Cargando…

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases()

BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted therapy of non–small cell lung cancer (NSCLC). Immunohistochemistry (IHC) is a sensitive and specific method to detect ALK protein expression, possibly an alternative to fluorescence in situ hybridizatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scattone, Anna, Catino, Annamaria, Schirosi, Laura, Caldarola, Lucia, Tommasi, Stefania, Lacalamita, Rosanna, Montagna, Elisabetta Sara, Galetta, Domenico, Serio, Gabriella, Zito, Francesco Alfredo, Mangia, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280637/ https://www.ncbi.nlm.nih.gov/pubmed/30529852 http://dx.doi.org/10.1016/j.tranon.2018.11.006

Ejemplares similares

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
por: Catino, Annamaria, et al.
Publicado: (2022)

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
por: Longo, Vito, et al.
Publicado: (2020)

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question—to treat or not to treat?
por: Cabillic, Florian, et al.
Publicado: (2018)

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
por: Vollbrecht, Claudia, et al.
Publicado: (2018)

Controversial role of mast cells in NSCLC tumor progression and angiogenesis
por: Longo, Vito, et al.
Publicado: (2022)

Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients()()
por: Catacchio, Ivana, et al.
Publicado: (2019)

A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung
por: Jia, Xiaojing, et al.
Publicado: (2022)

Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics
por: Śledzińska, Paulina, et al.
Publicado: (2022)

Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis
por: Ma, Hu, et al.
Publicado: (2016)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS
por: Zito Marino, Federica, et al.
Publicado: (2023)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR
por: Li, Yuan, et al.
Publicado: (2013)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods
por: Liu, Leilei, et al.
Publicado: (2015)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region
por: Bove, Samantha, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR
por: Wang, Jinghui, et al.
Publicado: (2014)

EML4-ALK Gene Mutation Detected with New NGS Lung Cancer Panel CDx Using Sputum Cytology in a Case of Advanced NSCLC
por: Morikawa, Kei, et al.
Publicado: (2023)

Immunoprofile from tissue microarrays to stratify familial breast cancer patients
por: Schirosi, Laura, et al.
Publicado: (2015)

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Vavalà, Tiziana, et al.
Publicado: (2021)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
por: Longo, Vito, et al.
Publicado: (2023)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients
por: Schirosi, Laura, et al.
Publicado: (2016)

Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
por: Montrone, Michele, et al.
Publicado: (2020)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
por: Wu, Yi-Cheng, et al.
Publicado: (2013)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
por: Xu, Chun-wei, et al.
Publicado: (2018)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tc38qes5mlakmh54qptqjou7ec